Physician
Bourassa, David
Bourassa, David was paid $145K by Medicaid between Jan 2018 and Dec 2024, across 12 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 65% of everything it billed.
33Billing provider infoBOURASSA, DAVID
WOONSOCKET, RI 02895
WOONSOCKET, RI 02895
33aNPI1215992870assigned 04/18/2006
33bProvider typePediatrics Physician
28Total paid$145K
24GClaims5,674
24DCodes billed12
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Rhode Island
Rank by total paid#123 of 265
Median peer was paid$133K
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,306 | $31K | |
| 2019 | 215 | $2K | |
| 2020 | 1,156 | $33K | |
| 2021 | 868 | $19K | |
| 2022 | 687 | $17K | |
| 2023 | 761 | $23K | |
| 2024incomplete | 681 | $20K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 65% | 1,423 | 1,341 | $94K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 17% | 2,672 | 2,590 | $25K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 8.1% | 518 | 425 | $12K |
| 90472 | Immunization administration, each additional vaccine (list separately) | 4.0% | 405 | 391 | $6K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.2% | 24 | 24 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.5% | 65 | 54 | $2K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 12 | 12 | $832.50 |
| 92551 | <1% | 130 | 120 | $775.68 | |
| 99177 | <1% | 168 | 168 | $724.68 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 25 | 25 | $360.40 |
| 0001A | <1% | 12 | 12 | $271.33 | |
| 90686 | <1% | 220 | 217 | $105.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.